Doxorubicin
Chronic progressive cardiac dysfunction linked to doxorubicin therapy for ALL
Published in Cancer Weekly, June 21st, 2005
According to a study from the United States, "Cross-sectional studies show that cardiac abnormalities are common in long-term survivors of doxorubicin-treated childhood malignancies. Longitudinal data, however, are rare."
"Serial echocardiograms (n=499) were obtained from 115 doxorubicin-treated long-term survivors of childhood acute lymphoblastic leukemia (median age at diagnosis, 4.8 years; median follow-up after completion of doxorubicin, 11.8 years)," explained S.E. Lipshultz and colleagues, University of Miami.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-06-21)
More Articles from Cancer Weekly
- Breast Cancer
Breast-conserving surgery compared to mastectomy as primary treatment modality - Epstein-Barr Virus
Cancer risk of gastric corpus linked to Epstein-Barr virus infection - Liposarcoma
Gains of 13q correlated with poor prognosis in liposarcoma - Prostate Cancer
High-dose regions linked to likelihood of cure after prostate brachytherapy - Acute Myeloid Leukemia
Wnt/beta-catenin pathway involved in acute myeloid leukemia pathogenesis - Amoxicillin
Amoxicillin interaction with DNA in human lymphocytes studied - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
